COMPLETED

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This main aim of this study is to check the level of knowledge and assess attitudes and behaviors of both participants and prescribing physicians regarding the risks and safe use of NATPARA. The survey will be done via internet, telephone, or paper and participants will be able to choose the method that is preferred. No study medicines will be provided to patients in this study.

Official Title

Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA® (Parathyroid Hormone) for Injection, for Subcutaneous Use

Quick Facts

Study Start:2015-09-01
Study Completion:2025-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05556629

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * A caregiver may participate in this survey on behalf of a participant who is a part of the SUP Program and who is eligible but unable to complete the survey.
  1. * Respondents who do not agree to participate in the survey will be excluded.
  2. * Survey respondents who have been employed or whose immediate family members have been employed by NPS, Shire, Takeda, United BioSource LLC, (UBC), or the Food and Drug Administration (FDA) are not eligible to participate in the survey and will be excluded.
  3. * Respondents who reported having a conflict of interest will be excluded.
  4. * Respondents who are not part of the SUP program will be excluded.

Contacts and Locations

Principal Investigator

Study Director
STUDY_DIRECTOR
Shire

Study Locations (Sites)

Shire-NPS Pharmaceuticals, INC. (Shire now part of Takeda)
Lexington, Massachusetts
United States

Collaborators and Investigators

Sponsor: Shire

  • Study Director, STUDY_DIRECTOR, Shire

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-09-01
Study Completion Date2025-11-30

Study Record Updates

Study Start Date2015-09-01
Study Completion Date2025-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Hypoparathyroidism